Status:
UNKNOWN
Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma
Lead Sponsor:
Singlera Genomics Inc.
Collaborating Sponsors:
Shanghai Zhongshan Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Brief Summary
This study aims to combine biomarker characteristic atlas and ctDNA detection technology to establish a precise standard scheme for minimal residual diagnosis of liver cancer after surgery and systemi...
Detailed Description
This study is a prospective, single-blind, randomized, controlled, single-center study. The patients with liver cancer are recruited after surgery or systemic treatment. Intraoperative cancer and para...
Eligibility Criteria
Inclusion
- Age 18-80 years old (including 80 years old), gender is not limited;
- Patients diagnosed with primary HCC;
- ECOG score ≤1;
- no previous malignant tumors, including liver cancer;
- Before blood collection, the patient had not received any treatment related to liver cancer, including surgery, transplantation, radiotherapy, chemotherapy, etc.;
- Survival period of ≥3 years as initially assessed by researchers;
- Those who are fully aware of this study and voluntarily sign the informed consent.
Exclusion
- Patients diagnosed with esophageal cancer, gastric cancer, colorectal cancer, lung cancer, pancreatic cancer, breast cancer and other malignant tumors;
- Patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months;
- Participate in other interventional clinical investigators within 3 months;
- Pregnant or lactating women;
- Patients with autoimmune diseases, genetic diseases, mental disorders/disabilities, substance abuse and other diseases deemed unsuitable for participation in the study by the researchers;
- Poor compliance, according to the judgment of the researcher can not complete the study.
Key Trial Info
Start Date :
December 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
475 Patients enrolled
Trial Details
Trial ID
NCT06178809
Start Date
December 25 2023
End Date
December 1 2025
Last Update
January 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan university Zhongshan Hospital
Shanghai, Shanghai Municipality, China, 200032